DE

470.26

-1.59%↓

FDX

245.41

+1.56%↑

PAYX

155.09

+0.39%↑

CPRT

57.56

+0.61%↑

HEICA

212.9

+0.18%↑

DE

470.26

-1.59%↓

FDX

245.41

+1.56%↑

PAYX

155.09

+0.39%↑

CPRT

57.56

+0.61%↑

HEICA

212.9

+0.18%↑

DE

470.26

-1.59%↓

FDX

245.41

+1.56%↑

PAYX

155.09

+0.39%↑

CPRT

57.56

+0.61%↑

HEICA

212.9

+0.18%↑

DE

470.26

-1.59%↓

FDX

245.41

+1.56%↑

PAYX

155.09

+0.39%↑

CPRT

57.56

+0.61%↑

HEICA

212.9

+0.18%↑

DE

470.26

-1.59%↓

FDX

245.41

+1.56%↑

PAYX

155.09

+0.39%↑

CPRT

57.56

+0.61%↑

HEICA

212.9

+0.18%↑

Search

Ocugen Inc

Gesloten

0.68 6.25

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

0.62

Max

0.7

Belangrijke statistieken

By Trading Economics

Inkomsten

-910K

-14M

Verkoop

-372K

764K

EPS

-0.05

Winstmarge

-1,816.754

Werknemers

95

EBITDA

-603K

-13M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+926.15% upside

Marktinformatie

By TradingEconomics

Marktkapitalisatie

57M

233M

Vorige openingsprijs

-5.57

Vorige sluitingsprijs

0.68

Technische score

By Trading Central

Vertrouwen

Weak Bullish Evidence

Ocugen Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

8 apr 2024, 14:32 UTC

Belangrijke Marktbewegers

Ocugen Gets FDA Clearance for IND Amendment for OCU400

Peer Vergelijking

Prijswijziging

Ocugen Inc Prognose

Koersdoel

By TipRanks

926.15% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 6.67 USD  926.15%

Hoogste 8 USD

Laagste 4 USD

Gebaseerd op 3 Wall Street-analisten die 12-maands prijsdoelen bieden voor Ocugen Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

3 ratings

3

Buy

0

Hold

0

Sell

Technische score

By Trading Central

0.6351 / 0.7995Steun & Weerstand

Korte Termijn

Weak Bullish Evidence

Gemiddeld Termijn

Strong Bullish Evidence

Lange Termijn

Bearish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.